AMBAR CLINICAL TRIAL DESIGN

International, multicenter, randomized, placebo-controlled and double-blind



Carried out in 41 hospitals (22 in U.S. and 19 in Spain)



496 patients
between 55 and 85
years old, with mild
and moderate
Alzheimer's



Designed to evaluate the efficacy of plasma exchange using different replacement volumes and concentrations of albumin



The patients were randomized into three treatment groups and a control group

The study was split into 2 phases:

PHASE 1

6 weeks

1 Total Plasma Exchange per week (2.5-3 liters of plasma)



PHASE 2

12 months

1 Low-Volume Plasma Exchange per month (650-880 ml of plasma)



Primary objective

To evaluate the efficacy of the treatment by measuring variations in:

- Patients' cognitive function
- · The ability to carry out daily activities

Evaluation method

- · Psychometric scales
- Neuroimaging
- Neuropsychological Test
- · Mini-Mental State Examination (MMSE)